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Global proﬁling of co- and post-translationally
N-myristoylated proteomes in human cells
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Protein N-myristoylation is a ubiquitous co- and post-translational modiﬁcation that has been
implicated in the development and progression of a range of human diseases. Here, we report
the global N-myristoylated proteome in human cells determined using quantitative chemical
proteomics combined with potent and speciﬁc human N-myristoyltransferase (NMT)
inhibition. Global quantiﬁcation of N-myristoylation during normal growth or apoptosis
allowed the identiﬁcation of 4100 N-myristoylated proteins, 495% of which are identiﬁed
for the ﬁrst time at endogenous levels. Furthermore, quantitative dose response for inhibition
of N-myristoylation is determined for 470 substrates simultaneously across the proteome.
Small-molecule inhibition through a conserved substrate-binding pocket is also demonstrated
by solving the crystal structures of inhibitor-bound NMT1 and NMT2. The presented data
substantially expand the known repertoire of co- and post-translational N-myristoylation in
addition to validating tools for the pharmacological inhibition of NMT in living cells.
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P
rotein N-myristoylation is a co- and post-translational
modiﬁcation in eukaryotes catalysed by the enzyme
N-myristoyltransferase (NMT), which transfers myristate
from myristoyl coenzyme A (Myr-CoA) to the N-terminal glycine
of a wide range of substrate proteins. Both human NMT
isozymes, NMT1 and NMT2, are expressed in most tissues and
have been implicated in the development and progression of
diseases including cancer1, epilepsy2, Alzheimer’s disease3,
Noonan-like syndrome4 and viral and bacterial infections5.
N-myristoylation is necessarily preceded by proteolysis to reveal
an N-terminal glycine, the only completely conserved motif
across all known NMT substrates. This may occur either co-
translationally when methionine aminopeptidase (MetAP) acts
on an N-terminal ‘MG’ motif at the ribosome, or post-
translationally at an internal site (Fig. 1a)6,7. Well-characterized
substrates include oncogene products, such as the tyrosine kinases
pp60c-src and pp60c-yes, and BID, a key mediator of apoptosis1.
The potential scope of NMT substrates is substantial; N-terminal
‘MG’ is present in ca. 7% of all gene products and is an excellent
substrate for MetAP, while site-speciﬁc proteolysis is ubiquitous
in cells, an example being caspase activity during apoptosis8.
Despite its importance in health and disease, direct identiﬁca-
tion of the N-myristoylated proteome in cells has been limited to
non-native low-throughput systems (for example, overexpression
of artiﬁcial protein constructs), and the vast majority of potential
co- and post-translational NMT substrates have not been
characterized in a native cellular context. We describe here a
chemistry-based approach to proﬁle selectively the co- and post-
translationally N-myristoylated proteome in human cells during
normal cell function and during apoptosis, which combines
quantitative chemical proteomics with a potent and speciﬁc
human NMT inhibitor. We present X-ray crystal structures of
human NMT1 and NMT2 providing structural evidence for a
highly conserved protein substrate-binding pocket, and
demonstrate selective target engagement and pharmacological
knockdown of N-myristoylation by an NMT inhibitor in live
cells. We also introduce a novel reagent that facilitates analysis of
the N-terminally modiﬁed peptide across a wide range of
substrates, including direct identiﬁcation of sites of post-
translational myristoylation. Global analysis of N-myristoylation
results in the identiﬁcation of 4100 N-myristoylated human
proteins, the majority of which are identiﬁed for the ﬁrst time in a
native cellular context. This global experimental strategy to deﬁne
the N-myristoylated proteome greatly expands the known
repertoire of co- and post-translational N-myristoylation
(PTMyr), and provides an approach to quantify inhibition of
NMT across dozens of substrate proteins simultaneously in
human cells.
Results
The targets of myristate analogue YnMyr in human cells. Lipids
tagged with an alkyne or azide moiety have emerged as powerful
tools to study protein lipidation in cells by virtue of their capacity
for metabolic incorporation and selective ligation to a range of
reporter labels9. One such example is YnMyr (tetradec-13-ynoic
acid), a tagged myristate analogue that has been shown to label a
variety of proteins in cells (Fig. 1b)10–12, and that was recently
used to proﬁle the myristoylated proteome in a protozoan
parasite13. While these studies demonstrate the potential of
YnMyr as a probe, it has yet to be applied to comprehensive
identiﬁcation of substrates and non-substrates in the complex
proteome of human cells. To address this challenge, we sought to
develop robust quantitative methods that can provide objective
measures to identify NMT substrates across the proteome in
living cells.
Initial studies using a ﬂuorogenic assay for NMT14 showed that
YnMyr in its CoA-ester form (YnMyr-CoA, see Supplementary
Methods for synthetic details) is transferred in vitro by both
NMT1 and NMT2 to the N-terminal glycine of a model substrate
peptide with comparable efﬁciency to the natural lipid
(Supplementary Fig. 1). Optimal metabolic incorporation of
YnMyr into proteins in a human cervical cancer cell line (HeLa)
was achieved after 24 h incubation at 20 mM YnMyr, as judged by
in-gel ﬂuorescence analysis following labelling of the alkyne
through copper-catalysed azide-alkyne cycloaddition (CuAAC)
with azido-TAMRA-PEG-Biotin (AzTB15, Supplementary Fig. 1).
There was no adverse effect on cell viability up to 3 days
with 100 mM YnMyr, and incorporation was effectively
outcompeted by myristate (Supplementary Fig. 1). Selective
enrichment of labelled proteins including known NMT
substrates (for example, PSMC1 (ref. 16), PRKACA17) could
be achieved through pull-down on streptavidin beads,
exploiting the biotin label on AzTB (Supplementary Fig. 1).
Quantitative proteomic analysis (label-free quantiﬁcation (LFQ),
n¼ 4, false-discovery rate (FDR)¼ 0.001) revealed that out of
4250 proteins enriched more than fourfold with YnMyr (relative
to a myristate control), 60% did not carry an N-terminal MG
motif; some of these proteins are S-palmitoylated or carry a
glycosylphosphatidylinositol (GPI) anchor, which may account
for enrichment of these proteins in a manner unrelated to N-
myristoylation by NMT (Supplementary Fig. 2b; Supplementary
Data 1). Proteins (108) carried an annotated N-terminal ‘MG’
motif, but these correlated only moderately with NMT substrates
predicted by bioinformatic tools (the Myristoylator18, Myr
Predictor19). Given the signiﬁcant limitations of this simple
enrichment approach, we envisaged that knockdown of human
NMT activity in cells in combination with quantitative chemical
proteomics would provide a robust and novel method for
proteome-wide experimental determination of the N-
myristoylated proteome in human cells.
A selective inhibitor of human NMT activity in cells. Co-
translationally N-myristoylated proteins are generated con-
tinuously through de novo protein synthesis (Supplementary
Fig. 1), and NMT is known to make direct interactions with the
ribosome and several other proteins, in addition to its cognate
substrates2. We considered that prompt and speciﬁc inhibition
of the catalytic activity of both NMT isozymes would provide a
precise and minimally disruptive tool to assist direct analysis
through quantitative chemical proteomics20,21. While genetic
approaches (RNA interference, gene knockout) can offer
speciﬁcity, they present some drawbacks as tools to assist
global quantitative chemical proteomic analysis of NMT
substrates. These include loss of non-catalytic protein
interactions of NMT, lethality of NMT knockouts22 and slow
and incomplete induction of knockdown23, leading to lack of
control over degree and timeframe of inhibition, and limited
applicability to myristoylation events occurring on short
timescales (for example, post-translational myristoylation
during apoptosis). These considerations prompted us to seek a
reagent for selective pharmacological knockdown of NMT
activity.
An ideal reagent for this purpose would be a dual NMT
inhibitor that acts selectively in mammalian cells, with minimal
disruption to normal cell function over the period of YnMyr
labelling. Compound 1 (Fig. 2a)24 is a potent dual NMT1/NMT2
inhibitor (half-maximal inhibitory concentration (IC50)¼ 17 and
22 nM, respectively)14 and inhibits myristoylation of an
overexpressed protein construct in-cell-based microscopy
assays25,26; we previously validated 1 as a highly selective tool
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for knockdown of NMT activity in protozoan parasites13.
To validate this chemotype as a pharmacological tool in human
cells, we determined the binding mode of 1 in a human NMT1/
myristoyl-CoA complex through X-ray crystallography to 2.1 Å
resolution, and compared this structure with those of binary
complexes of NMT1 and NMT2 solved to 1.7 and 2.3 Å
resolution, respectively (Fig. 2b; Table 1; Supplementary Fig. 3,
PDB 4C2Z, 4C2Y, 4C2X). These structures provide comparative
atomic resolution insight into the human NMT enzymes,
showing the very similar arrangement of residues in the
human NMT1 and NMT2 active sites. 1 binds at the protein
substrate-binding pocket in the presence of Myr-CoA, and
interacts with minimal disturbance of side-chain geometry,
suggesting that it binds tightly to a pocket pre-organized by
binding of myristoyl-CoA27, and conﬁrming its conserved
mode of action as a dual NMT1/2 inhibitor. 1 had no effect on
HeLa cell viability, as measured by the metabolic activity assay
(MTS), after 24 h incubation at concentrations up to 10 mM
(Fig. 2c). This notable lack of acute toxicity suggests that 1 is a
non-disruptive tool to assist analysis of NMT substrates in
cells and is consistent with selective NMT inhibition, since the
pre-existing pool of N-myristoylated proteins would be expected
to maintain cell viability until depleted. In line with this
hypothesis, a gradual and dose-dependent decrease in cell
viability occurred over time in the presence of 1. A plateau of
metabolic activity was observed up to 10 mM 1, and the level of
this plateau diminished with extended duration of inhibition,
with a consistent effector concentration for half-maximum
response (EC50) of 210±15 nM. We hypothesize that this time-
dependent response is characteristic of on-target, selective NMT
inhibition in mammalian cells.
Treatment of HeLa cells with YnMyr (20 mM) and 1 (0–5 mM)
for 24 h resulted in a robust dose-dependent decrease in
labelling intensity for the major TAMRA-labelled bands, with
maximal inhibition occurring by 5 mM 1 (Fig. 2d). Direct
quantiﬁcation of ﬂuorescence intensity revealed an apparent
in-cell ‘tagging IC50’ (hereafter referred to as TC50) of
170±31 nM (Fig. 2a), suggesting good uptake of this inhibitor
in mammalian cells. Furthermore, enrichment and western
blotting (WB) of YnMyr-tagged proteins revealed potent dose-
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Figure 1 | Quantitative chemical proteomic strategy for global proﬁling of NMT substrates in mammalian cells. (a) N-terminal N-myristoylation
occurs co-translationally following action of methionine aminopeptidase (MetAP) at the ribosome, or post-translationally following cleavage by a protease.
An N-terminal glycine residue is the only fully conserved element of the substrate. (b) Chemical proteomic workﬂow. Cells cultured in normal media
with YnMyr and NMT inhibitor were lysed and spiked with a ﬁxed quantity of lysate from cells cultured in SILAC media (R10K8 labelled) with YnMyr.
Labelled proteins were captured by CuAAC with AzTB, afﬁnity enriched and classiﬁed as substrates (or non-substrates) according to the response of
enrichment to inhibition determined by quantitative proteomics (nanoLC-MS/MS, MaxQuant, Perseus and GraFit 7.0).
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dependent inhibition of N-myristoylation for several known
NMT substrates, including c-Src tyrosine kinase (Fig. 2d). The
TC50 value is closely similar to the EC50 noted above, and
the plateau effect observed in the viability assay corresponds
to inhibitor concentrations above which NMT is fully inhibited,
providing additional evidence for on-target mode of action
in cells. NMT-catalysed myristoylation generally occurs co-
translationally during normal cell function, and so we further
conﬁrmed that 1 did not signiﬁcantly affect protein synthesis in
cells, which could in principle lead to an observed reduction in
levels of myristoylated proteins. Protein labelling by azidoho-
moalanine, an established probe for protein synthesis28,
was quantitatively blocked by the protein synthesis inhibitor
cycloheximide, but was unaffected by 24 h treatment with 1 at a
concentration 430-fold higher than TC50 (Fig. 2e). Finally,
quantitative whole-proteome analysis of a total of 1,069 proteins
following 24 h treatment with 1 conﬁrmed that 496% show no
signiﬁcant (Po0.05) change in abundance, and 499.9%
remained within twofold of the untreated control (Supplemen-
tary Fig. 4).
Taken together, these data demonstrate that 1 is a potent,
protein substrate-competitive, dual NMT1/NMT2 inhibitor, and
a highly selective pharmacological tool for inhibition of NMT
activity in cells.
Co-translational substrates and non-substrates of NMT. So-
called ‘spike-in’ SILAC (stable isotope labelling by amino acids in
cell culture) quantitative proteomics has recently emerged as a
straightforward method to incorporate heavy isotope-labelled
standards in a quantitative proteomics workﬂow29, and we
considered that a combination of spike-in SILAC with YnMyr
tagging and chemical NMT inhibition would provide a powerful
platform for comprehensive analysis of NMT substrates in cells
(Fig. 1b). This approach normalizes all samples across all sample-
handling steps (CuAAC ligation, pull-down, sample preparation
and nanoliquid chromatography-mass spectrometry (LC-MS)/
MS), and does not require heavy isotope labelling of experimental
samples, thus eliminating any potential disruption to the system
under study. Accordingly, protein lysate from HeLa cells labelled
with 15N413C6-arginine and 15N213C6-lysine (‘R10K8’) and tagged
with YnMyr was used as an internal spike-in SILAC standard for
proteins labelled in HeLa cells cultured in normal media in
the presence of YnMyr (20 mM) and an increasing concentration
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Figure 2 | Characterization of potent and selective NMT inhibitors. (a) Structure and dual NMT1/NMT2 inhibitory potency of compound 1. (b) Crystal
structure of 1 (grey) bound to NMT1 in the presence of Myr-CoA showing key water molecules (red spheres) and polar interactions (dashed lines).
Key residues (NMT1 numbering) are shown for NMT1 (blue, PDB 4C2Y) and NMT2 (pink, PDB 4C2X), and for NMT1 with 1 bound (green, PDB 4C2Z).
Myr-CoA or the Myr-CoA analogue (NHM) is shown in black/grey. Image generated in PyMOL (0.99rc6, DeLano Scientiﬁc LLC, http://
pymol.sourceforge.net/). (c) Viability (MTS assay) of HeLa cells exposed to compound 1 at concentrations and time points indicated; error bars, s.d.
(n¼6). (d) Compound 1 inhibits NMT activity dose-dependently in HeLa cells (BPD¼ before pull-down; PD¼ after pull-down on streptavidin-coated
beads). In-gel ﬂuorescence after YnMyr tagging was quantiﬁed (ImageJ) and the response (% relative intensity; error bars, s.d. (n¼ 2)) plotted using GraFit
7.0 to determine TC50 (see Fig. 2a for TC50 determined for compound 1). Western blots against protein substrates of NMTshow dose-dependent reduction
in enrichment following inhibition (tubulin: non-substrate loading control). (e) Cells treated with azidohomoalanine (AHA), cycloheximide (CHX) or
inhibitor 1 (or DMSO vehicle), were lysed and ligated (CuAAC) to an alkyne-TAMRA reagent67. In-gel ﬂuorescence demonstrates inhibition of protein
synthesis by CHX, but not by 1.
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of compound 1 (0–5 mM). Pull-down and on-bead tryptic
digestion enabled quantiﬁcation of proteome-wide changes in
N-myristoylation in response to inhibition, determined in ﬁvefold
replicate experiments for each of six concentrations of 1 on a
nanoLC-MS/MS platform (see below and Supplementary
Methods for details of proteomic analyses).
More than 400 proteins without an N-terminal MG motif
identiﬁed in these experiments showed no response to inhibition,
as expected for non-substrates of NMT. For 169 enriched proteins
carrying an N-terminal MG motif, 17,401 unique protein-derived
peptide sequences were identiﬁed and quantiﬁed with high
(499.9%) conﬁdence, resulting in 20,084 spike-in SILAC ratios
for which the response to inhibition was analysed (Supplementary
Data 2). These proteins partitioned into distinct populations of
responding and non-responding proteins (Fig. 3a). Seventy
proteins showed a robust response to inhibition and could thus
be assigned with high conﬁdence as substrates of NMT in cells,
while a further 27 substrate proteins were assigned with lower
conﬁdence since analysis was based on a smaller set of unique
peptides, due to the lower abundance of these proteins
(Supplementary Data 2). Enrichment of substrate proteins
exhibited a sigmoidal response to NMT inhibition (shown for
three known NMT substrates in Fig. 3b) enabling an in-cell IC50 to
be calculated per substrate, whereas that of non-substrates
remained unaffected (Fig. 3c). The enrichment of 56 proteins
bearing an N-terminal MG did not respond to NMT inhibition up
to the highest concentration tested, and these proteins were
therefore classiﬁed as non-substrates. The mean in-cell IC50 across
NMT substrates was found to be 168±38nM, closely comparable
to the TC50 value from in-gel ﬂuorescence, with an excellent ﬁt to a
standard dose-response curve for the large majority of substrates
(mean slope factor¼ 1.21±0.3) (Fig. 3d). The dose response for
three examples of newly discovered substrates (HCCS, FLOT2 and
MARC2) was probed by WB following pull-down, and all were
found to follow the same trend determined by quantitative
proteomic analyses (Supplementary Fig. 5). The inhibitor sensi-
tivity of myristoylation of the large majority of substrates lies
within 10-fold of the average in-cell IC50, with an overall range of
sensitivity to inhibition of about 100-fold. We hypothesize that
numerous factors may contribute to this interesting and subtle
variation in substrate sensitivity observed in a cellular system,
including subcellular localization, dynamic rate of synthesis in the
cell, afﬁnity for the enzyme-binding pocket, rate of leader Met
removal by MetAP and complex interactions with the ribosome
and potentially other proteins.
To provide further cross-validation of NMT substrates identiﬁed
through this novel quantitative approach, we undertook proﬁling
of the N-terminally modiﬁed peptides identiﬁed during chemical
proteomic analysis using multifunctional reagents for capture of
YnMyr-tagged proteins. Here we applied our previously reported
reagent AzKTB13 and a novel reagent AzRTB, each of which
incorporates a trypsin-cleavable site that enables release of the
modiﬁed peptide with a hydrophilic Lys or Arg tag during protein
digest for subsequent proteomic analysis (Supplementary Fig. 6).
Applying these tools to the HeLa system above, we directly
identiﬁed a total of 38 N-terminally YnMyr-modiﬁed peptides by
MS/MS (Fig. 3a; Supplementary Fig. 7). The majority of peptides
(27) were common to both reagents, with AzRTB providing
identiﬁcation of an additional 9 substrates over AzKTB
(Supplementary Data 2); the improved performance of AzRTB
Table 1 | X-ray data collection and reﬁnement statistics.
HsNMT2-NHM HsNMT1-Myr-CoA HsNMT1-Myr-CoA-1
PDB accession code 4C2X 4C2Y 4C2Z
Data collection
Cell dimensions (Å) a, b, c 49.70, 72.32, 114.69 78.74, 178.48, 58.55 78.63, 179.12, 58.59
Space group P212121 P21212 P21212
Resolution (Å)* 57–2.33 (2.41–2.33)* 72–1.64 (1.67–1.64) 89–2.08 (2.14–2.08)
Rsym (%) 6.1 (64.4) 7.0 (70.6) 15.0 (68.6)
I/sI 15.2 (2.8) 17.7 (2.4) 12.9 (3.4)
Completeness (%) 99.9 (99.9) 98.2 (85.0) 100 (100)
Redundancy 6.3 (6.6) 7.1 (6.0) 7.1 (7.1)
CC1/2
w 1.0 (0.84) 1.0 (0.75) 1.0 (0.85)
Reﬁnement
No. of unique reﬂections 18,414 98,990 50,468
Rwork/Rfree 21.8/28.8 17.0/22.1 16.9/23.8
No. of atoms 3,345 7,569 7,221
Protein 3,212 6,571 6,434
Ligand NA NA 64
Co-factor 64 126 126
Water 68 802 537
B-factors (Å2)
All atoms 54.4 22.0 25.9
Protein 54.5 20.9 25.3
Ligand NA NA 41.2/78.6z
Co-factor 45.2 15.7 18.7
Water 49.5 30.0 29.9
r.m.s.d.y
Bond lengths (Å) 0.013 0.021 0.023
Bond angles () 1.672 2.230 2.283
NA, not applicable; PDB, protein database.
*Highest resolution shell is shown in parentheses.
wPearson correlation coefﬁcient between two random half-data sets68.
zB-factor for ligand in chain A/chain B.
yr.m.s.d. of bond lengths or bond angles from ideal geometry.
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may arise from enhanced on-bead proteolytic digestion, or
superior chromatographic and mass spectral properties.
Incomplete coverage of the tagged proteome through this
approach is expected due to low detectability of certain modiﬁed
peptides, for example, from sequence homology in the N-terminal
tryptic peptide, the presence of multiple Lys or Arg residues
proximal to the modiﬁcation site, poor chromatographic or
ionization proﬁles or abundance below the detection limit.
Nevertheless, over 50% of substrates identiﬁed through
quantitative proteomics (above) were directly validated by MS/
MS sequencing of the N-terminally tagged peptide. Importantly, all
38 tagged sequences correspond to the N-terminal peptide of NMT
substrates identiﬁed here, and there was no evidence for peptide
modiﬁcation within the non-substrate set (Fig. 3a; Supplementary
Data 2), providing self-consistent validation of the approach.
Of the substrates of NMT identiﬁed here, o25% have
previously been reported in experiments with chemically tagged
myristate analogues (Supplementary Data 2 and Supplementary
Table 1)12,30. We attribute this marked improvement to our new
approach incorporating quantitative proteomics and selective
inhibition, coupled to high-sensitivity mass spectrometry. Only
ﬁve of the substrates identiﬁed here have previously been shown
7
6
5
4
3
2
1
0
–1
c-Src
MARC2 HCCS
PRKACA
PSMC1
FLOT2
GOLIM4
CD81Lo
g 2
 
m
a
xi
m
u
m
 r
e
sp
on
se
to
 N
M
T 
in
hi
bi
tio
n
7
a
c
e f
d
b
6
5
4
3
2
1
0
–1
All proteins
In-cell dose response
(all substrates)
In-cell dose response
(selected substrates)
PRKACA
PSMC1
c-Src
FLOT2
MARC2
HCCS
Log2 enrichment
1 3 5 7 119
PTGFRN
High confidence
Low confidence
YnMyr peptide ID
Non-substrates
1
0.8
0.6
0.4
0.2
0
GOLIM4
CD81
PTGFRN
R
es
po
ns
e
En
ric
hm
en
t
1
0.8
0.6
0.4
0.2
0
0.05 0.5 5
PSMC1
PRKACA
c-Src
0.005 0.05 0.5 5
Inhibitor 1 (μM)
0.0005 0.05 5
Inhibitor 1 (μM)Inhibitor 1 (μM)
N-myristoylated substrates identified in this study
Previously identified
at native abundance
(5, 7%)
Not previously
experimentally
determined
(26, 37%)
Identified for the
first time in cells
(13, 19%)
Identified for the first time
at native abundance
(26, 37%)
0.005 0.05 5
Inhibitor 1 (μM)
Cellular protein
localization, 2
Phosphatase,
4Lyase or
ligase, 3
Organelle
biology, 5
Transcription,
3
Apoptosis, 2 Signal
transduction, 5 Redox, 6
Other, 8
Kinase, 8
Unknown, 9
Protein
transport, 11
Transferase, 2
Cell cycle
regulation, 2
1
0.8
0.6
0.4
0.2
0
R
es
po
ns
e
1
0.8
0.6
0.4
0.2
0
Figure 3 | Identiﬁcation of co-translational NMT substrates in HeLa cells. (a) Log2-fold change for maximal response of YnMyr enrichment of MG-
initiated proteins to NMT inhibition (compound 1, six concentrations, 0–5mM, n¼ 5) quantiﬁed by spike-in SILAC, plotted against enrichment relative to
myristic acid fed control (by LFQ, see Supplementary Fig. 2). Circles plot substrates (green), substrates identiﬁed with lower conﬁdence/fewer unique
peptides (yellow) and non-substrates (grey circle); triangles indicate substrates for which a YnMyr-modiﬁed peptide was identiﬁed directly by MS/MS
using AzRTB and/or AzKTB. Vertical scatter plot (at right) shows responses for all proteins identiﬁed, including those lacking quantiﬁable peptides in the
myristate control. (b) Response of enrichment to NMT inhibition quantiﬁed by spike-in SILAC for the three known NMTsubstrates in Fig. 2d; error bars, s.d.
(n¼ 5). (c) Enrichment for three non-substrates shows no signiﬁcant response up to the highest concentration of 1 tested; error bars, s.d. (n¼ 5).
(d) Dose-response curves for NMTsubstrates identiﬁed by quantitative chemical proteomics. Plots were generated by non-linear regression of IC50 values
and slope factors to a standard dose-response equation (GraFit 7.0). Three known (PRKACA, c-Src and PSMC1) and three novel (FLOT2, MARC2 and
HCCS) substrates are highlighted at the right. (e) Proportion of substrates identiﬁed here for the ﬁrst time at their endogenous (native) expression level in
live mammalian cells (green slices) vs those previously identiﬁed under the same conditions (white slice). (f) Biological functions for 70 NMT substrates
identiﬁed in this study (Gene Ontology annotations).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5919
6 NATURE COMMUNICATIONS | 5:4919 | DOI: 10.1038/ncomms5919 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
to be N-terminally myristoylated at an endogenous expression
level in mammalian cells, for example, by immunoprecipitation
(IP) of a substrate coupled to metabolic radiolabelling or mass
spectrometry (Fig. 3e). Considering only the highest conﬁdence
assignments, 65 NMT substrates were identiﬁed here for the ﬁrst
time at endogenous abundance in live cells (that is, without
overexpression of protein constructs), 39 for the ﬁrst time in a
cell-based context and 26 for the ﬁrst time by any experimental
approach. Very few bioinformatic predictions have been validated
experimentally at native protein abundance in cells, and the two
publicly available predictors disagree or conﬂict with prior
evidence for N-myristoylation in several cases, particularly for
lower conﬁdence predictions (Supplementary Fig. 8)18,19,31.
Classifying our NMT substrates into groups by prediction
conﬁdence (see Supplementary Methods), we found that the
majority of substrate and non-substrate predictions were
supported by experimental evidence (Fig. 3e). As expected,
there was excellent (96%) accuracy for ‘high’ conﬁdence predicted
substrates, and the accuracy of predictions fell in line with
conﬁdence, with 17% ‘medium’ and 33% ‘low’ conﬁdence
predictions showing no response to NMT inhibition. A handful
of ‘high’ conﬁdence predictions were contradicted by evidence in
cells (for example, GOLIM4, Fig. 3c), and 10% of non-substrate
predictions were found to be inaccurate (for example, MARC2,
FLOT2). These data offer the ﬁrst comprehensive assessment of
the in vivo accuracy of in silico NMT substrate predictions, and
provide strong support for the accuracy of the conﬁdence
heuristics built into the most commonly used prediction tools.
Previously determined estimates for the total number of distinct
protein sequences expressed at a detectable level in HeLa cells
(10,255)32 and the proportion of the human proteome predicted
to be myristoylated (0.8%)31 suggest that about 80 proteins may
be myristoylated in HeLa cells. This prediction is in good
agreement with the total of 70 (at high conﬁdence) to 97
(including lower conﬁdence) substrates found here.
Taken together, these data provide the ﬁrst proteome-wide
determination of the substrates of NMT in a living system, and
greatly expand the range of NMT substrates validated in vivo. A
survey of functions by gene ontology annotation33 revealed
distribution across a wide range of pathways in the cell (Fig. 3f),
and an expected strong bias towards organelle and membrane
localization (Supplementary Fig. 9).
Proﬁling PTMyr during apoptosis. N-myristoylation occurs
mainly co-translationally during basal cell function; however,
during apoptosis the protein BID (which mediates release of
cytochrome c from mitochondria) has been shown to be post-
translationally cleaved and N-myristoylated at endogenous
expression levels34. There is also evidence for a small number of
additional proteins under conditions of overexpression35
(Supplementary Table 2). The extent of PTMyr during
apoptosis has not been systematically determined to date, and
no reliable bioinformatic tool exists to predict PTMyr.
Interestingly, NMT1 and NMT2 are also cleaved during
apoptosis to generate new catalytically active species, which
may also induce a change in substrate proﬁle36. To determine the
potential of our approach for proﬁling PTMyr during apoptosis,
we ﬁrst demonstrated apoptosis-dependent labelling of new N-
myristoylated proteins in cells treated with staurosporine (STS), a
broad spectrum kinase inhibitor that is a potent inducer of
apoptosis37. Co-translational myristoylation was strongly
downregulated on treatment with STS as judged by gel-based
imaging, consistent with rapid inhibition of de novo protein
synthesis. Furthermore, a new band pattern was observed that
was readily inhibited by 1 without affecting robust induction of
cleavage of markers of apoptosis (PARP, BID and NMT1)
(Fig. 4a). SILAC-based quantiﬁcation of YnMyr-tagged proteins
further conﬁrmed that labelling of most co-translationally N-
myristoylated substrates is substantially reduced on STS
treatment, while a subset of proteins that do not carry an
N-terminal MG motif in the full-length protein are enriched
(Supplementary Data 3). Combining our methodology for
quantitative determination of sensitivity to NMT inhibition
with STS-dependent enrichment, we identiﬁed 35 high-
conﬁdence and 5 low-conﬁdence PTMyr proteins (Fig. 4b;
Supplementary Data 4), including BID, four other proteins with
prior evidence supporting PTMyr (Gelsolin, MACF1, PAK2 and
YTHDF2) and 35 novel substrates. Using the optimized
multifunctional reagent AzRTB, a total of 12 YnMyr-tagged
peptides were identiﬁed from whole-proteome analysis and
sequenced by MS/MS (Supplementary Fig. 10; Supplementary
Data 4). All 12 modiﬁed peptides were found to contain an
N-terminal YnMyr-glycine motif, and were derived from proteins
in the high-conﬁdence PTMyr data set (Fig. 4b), including
numerous novel substrates. For each of these proteins, the site of
cleavage and PTMyr was mapped to a speciﬁc glycine residue
(Supplementary Fig. 11). Interestingly, all 12 modiﬁed sites are
preceded by aspartate, suggesting apoptosis-induced cleavage by
caspases, and the majority of the resulting new N termini are
predicted as NMT substrates with medium or high conﬁdence
(Supplementary Data 4). BID34 and novel substrate cytoplasmic
dynein 1 intermediate chain 2 (Dync1i2)38 were probed by WB
following pull-down (Fig. 4c), conﬁrming inhibitor-sensitive
enrichment of an intact PTMyr substrate at native abundance.
PTMyr was also conﬁrmed in HeLa cells for another novel
substrate, Culin 4B39, using a C-terminal FLAG-tagged construct
(Cul4B[1-590]-FLAG) and an IP/on-resin ligation protocol13,40.
YnMyr tagging was followed by IP with anti-FLAG, and CuAAC
ligation to azido-TAMRA enabled inhibitor-sensitive ﬂuorescence
imaging of the cleaved product (Fig. 4d).
This ﬁrst proteome-wide analysis of PTMyr in the context of
apoptosis reveals a remarkable range of functions for novel
PTMyr proteins, including ubiquitination, cytoskeleton remo-
delling and regulation of cell survival; more than half are
localized to the nucleus or cytoskeleton prior to apoptosis
(Fig. 4e).
Discussion
Here we have found that simple chemical proteomic analysis
based on metabolic labelling with tagged lipids has limited
speciﬁcity, and results in identiﬁcation of a large number of non-
myristoylated proteins that may be due to a combination of
metabolism, the lipid substrate promiscuity of protein S-acylation
and incorporation into GPI anchors. However, we have shown
that augmenting this analysis with sensitive quantitation of the
impact of a selective NMT inhibitor allows robust differentiation
of substrate and non-substrate proteins. Our data emphasize the
importance of experimental determination of co- and post-
translational myristoylation, and suggest that bioinformatic
predictors of N-myristoylation may beneﬁt from further reﬁne-
ment. The capacity to determine inhibition sensitivity of dozens
of substrates simultaneously will be of particular interest in future
drug discovery efforts aimed at targeting NMT for therapeutic
beneﬁt, for example, in cancer, and in assessing potential
mechanism-based host toxicity of NMT inhibitors as drugs for
infectious disease. The data obtained here suggest that the
interplay between NMT inhibition and cell fate is likely to be
complex, arising from potential loss of function in dozens of
speciﬁc NMT substrate proteins, and changes in the function of
many more PTMyr proteins on induction of apoptosis. However,
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our approach provides the ﬁrst method to analyse and under-
stand this complexity by enabling direct, multiplexed quantiﬁca-
tion of inhibitor response in live cells. Our studies reveal a range
of sensitivity to NMT inhibition between substrates; as noted
above, there are multiple possible explanations for this ﬁnding.
It may be supposed that under normal circumstances NMT
activity is not limiting, but on inhibition there may be increased
competition between substrates for a substantially reduced pool
of active NMT. However, we also note that the situation in vivo is
complex and dynamic, and thus it is important to consider
substrate sensitivity in living cells rather than in a simple
enzyme–substrate complex formed in vitro. Previous studies
suggest that NMT1 and NMT2 possess both distinct and
overlapping biological roles. Comparison of the ﬁrst crystal
structure of NMT2 with that of NMT1 reveals a highly conserved
active site, consistent with similar kinetic parameters in simple
recombinant enzyme assays. We therefore hypothesize that any
potential differences in substrate selectivity are driven by NMT–
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Figure 4 | Identiﬁcation of post-translational NMT substrates in HeLa cells during STS-induced apoptosis. (a) Cells were treated with STS, YnMyr and
NMT inhibitor 1 (or DMSO vehicle) and proteins ligated (CuAAC) to AzTB and analysed by in-gel ﬂuorescence (top), Coomassie staining (loading control)
or western blots with antibodies against three markers of apoptosis, showing cleavage of PARP, NMT1 and BID (lower panels). Lanes marked ( ) were
treated with DMSO vehicle. STS does not affect background labelling (lanes 1–2), and NMT inhibition knocks down labelling in the presence or absence of
STS (lanes 5–6). (b) Log2-fold change for maximal response of YnMyr enrichment of proteins to NMT inhibition during apoptosis (compound 1, ﬁve
concentrations 0–1mM, each n¼ 3) quantiﬁed by spike-in SILAC, plotted against median-centred enrichment relative to non-apoptotic control, quantiﬁed
by SILAC. Circles plot post-translational substrates (blue), borderline substrates (yellow) and non-substrates (white/grey); triangles indicate substrates for
which a YnMyr-modiﬁed peptide was identiﬁed directly by MS/MS. Plot at right shows inhibitor response for proteins found only following treatment with
STS (that is, detected only under conditions of apoptosis). Selected protein IDs are indicated, with previously known substrates in italics. (c) Cells were
treated with STS, YnMyr and NMT inhibitor 1 (or DMSO vehicle) and tagged proteins ligated (CuAAC) to AzTB and analysed by western blot against BID
and Dync1i2 (BPD¼ before pull-down; PD¼ after pull-down on streptavidin-coated beads). Cleaved BID (ca. 15 kDa) or Dync1i2 (ca. 65 kDa) are enriched
in an inhibitor-sensitive manner. (d) A C-terminal FLAG-tagged Culin 4B construct (Cul4B[1-590]-FLAG, Addgene) was overexpressed in HeLa cells for
17 h, whereupon the cells were treated with STS, YnMyr and NMT inhibitor 1 (or DMSO vehicle), as above. Proteins were immunoprecipitated (anti-FLAG),
ligated (CuAAC) to AzT (azido-TAMRA) and analysed by in-gel ﬂuorescence and by western blot; inhibitor-sensitive labelling of PTMyr Cul4B was
observed at ca. 62 kDa; anti-actin western blot of IP supernatant provides loading control. (e) Biological functions and localization for the 40 post-
translational substrates of NMT identiﬁed in this study (GO annotations).
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ribosome interactions, subcellular localization and other factors
that can only be recapitulated in native, intact human cells.
Future studies to identify NMT1- and NMT2-speciﬁc substrates
could exploit our approach in combination with isozyme-speciﬁc
knockdown.
Numerous important pathways involve proteins that are shown
here for the ﬁrst time to be co- or post-translationally
N-myristoylated at their endogenous abundance in cells. A few
notable co-translational examples in mitochondria include
ligation of haem to cytochrome c (HCCS)41, activation of
hydroxylated prodrugs and regulation of nitric oxide synthesis
(mARC1, mARC2)42 and NADH dehydrogenation (NDUFAF4,
NDUFB7)43. Among numerous novel targets involved in essential
trafﬁcking pathways, we discovered N-myristoylation of
LAMTOR1 (ref. 44), which anchors the scaffolding complex of
the mTORC1 and MAPK pathways, and Battenin/CLN3 (ref. 45),
mutations of which can result in Batten disease, a fatal inherited
neurodegenerative disorder. Novel substrates also include
proteins that mediate nuclear processes; for example, nucleolar
protein 3 (NOL3/ARC), which acts to inhibit apoptosis, has
attracted much recent attention for its role in promoting
tumorigenesis, metastasis and chemoresistance in a variety of
cancers46, and as a mediator of pulmonary hypertension47.
PTMyr substrates are equally diverse in function. They include
components of the ubiquitination machinery such as STAMBPL1,
a metalloprotease that cleaves Lys-63 polyubiquitin48, E2 ligase
UBE2O49 and Cullin 4B39, a core member of E3 ligase complexes
involved in cell cycle regulation and the response to ultraviolet-
induced DNA damage. MACF1 (ref. 50) facilitates actin–
microtubule interactions, while Dync1i2 (ref. 38) and CLASP2
(ref. 51) regulate microtubule dynamics during cell division.
Among several regulators of cell survival, we identiﬁed death
inducer-obliterator 1 (DIDO1), which is upregulated during
apoptosis and implicated in melanoma progression52, and Nestin,
an intermediate ﬁlament protein and putative cancer stem cell
marker53. Taken together, these data indicate many potential
novel roles for myristoylation that merit future investigation in
both basal cell function and apoptosis, with signiﬁcant
implications for basic biology, and for drug development
targeting NMT.
We have demonstrated here that a combination of sensitive,
quantitative chemical proteomic analyses with a well-character-
ized, highly selective pharmacological tool can proﬁle the
substrates of co- and post-translational modiﬁcation across the
proteome, at native abundance in living cells. Furthermore, we
have shown that this toolbox can be expanded using another
chemical tool (STS) to proﬁle post-translational modiﬁcation
events during apoptosis. Selective and cell-active chemical
inhibitors and proteomic tools are available for an increasing
range of enzymes and chemical modiﬁcations. Where these tools
have been sufﬁciently well validated, we anticipate that our
method will have wide future applicability for understanding
modiﬁcation proﬁles in living cells under native conditions.
Methods
Synthetic procedures are reported in Supplementary Information.
General methods. Culture media and reagents for HeLa cell culture were obtained
from Sigma-Aldrich, Gibco (Life Technologies), Iris Biotech, A&E Scientiﬁc (PAA).
Fluorescence on the gel was recorded using an ETTAN DIGE Imager (GE
Healthcare). Chemiluminescence was recorded using a LAS-3000 Imaging System
(Fujiﬁlm). Absorbance in 96-well plates was measured using a SpectraMax M2/
M2e Microplate Reader from Molecular Devices.
For quantitative proteomics (spike-in SILAC and SILAC), R10K8 and R0K0
Dulbecco’s modiﬁed Eagle’s medium (DMEM) media were purchased from
Dundee Cell Products. Cell dissociation buffer (enzyme free, phosphate-buffered
saline (PBS) based), obtained from Gibco (Life technologies) was used instead of
trypsin to detach the cells before passaging. Dialysed fetal bovine serum (FBS) was
obtained from Sigma-Aldrich. For proteomics, all buffers were ﬁltered using a
0.2-mM ﬁlter. Low-binding tubes (Protein LoBind tubes, Eppendorf) were used to
carry out the enrichment of NMT substrates for MS-based proteomics and to
freeze-dry the digested peptides. Plasmid encoding C-terminally FLAG tagged
Cul4B (aa1-590) was obtained from Addgene, TurboFect transfection reagent was
from Thermo Scientiﬁc, ANTI-FLAG M2 Afﬁnity Gel was from Sigma-Aldrich.
N3-TAMRA was purchased from Life Technologies.
Enzymatic assay. Kinetic studies and IC50 values determinations were carried out
using a 7-diethylamine-3-(40maleimidylphenyl)-4-methylcoumarin ﬂuorescence
assay, as described by Goncalves et al.14 The full-length NMT1 and NMT2 enzymes
were produced as described previously and used at a ﬁnal concentration of
300 ngml 1 (ref. 14). For kinetic studies, the initial rates are the mean of three initial
rates determined with Wallac EnVison Manager Software. The data were ﬁtted to the
enzyme kinetics function in GraFit 7.0 (Erithacus Software Ltd, UK). IC50 values are
the mean value of two or more determinations, and IC50 values were determined
using GraFit 7.0 (Erithacus Software Ltd) by non-linear regression ﬁtting.
Protein production and X-ray crystallography. The catalytic domains of HsNMT
isoforms 1 and 2 were produced as His-tagged proteins and puriﬁed as described
previously14. Crystals of HsNMT1 (after removal of the puriﬁcation tag with 3C
protease) and HsNMT2 (with the N-terminal His-tag intact) were obtained by the
vapour diffusion method. Binary complexes of HsNMT1 (6mgml 1 in 25mM
Tris–HCl pH 7.5, 100mM NaCl, 1mM dithiothreitol (DTT)) and Myr-CoA(5%
volume added of 10mM solution in 50% dimethyl sulphoxide (DMSO)) were
crystallized by adding an equal volume of 22.5% polyethylene glycol (PEG) 4000,
5mM NiCl2, 100mM sodium citrate (pH 4.5) containing 2.5% glycerol as
cryoprotectant. A ternary complex of HsNMT1 containing both co-factor and
ligand 1 (added as 5% volume of a 10-mM solution in 50% DMSO) was crystallized
using 25% PEG 2000 monomethyl ether, 0.2M KBr, 100mM sodium citrate (pH
4.5) containing 5% glycerol. HsNMT1 crystals belong to the orthorhombic space
group P21212 with two molecules of the complex in the asymmetric unit. HsNMT2
(7.5mgml 1 in 25mM Tris pH 7.5, 100mM NaCl, 1mM DTT) was crystallized as
a binary complex with the non-hydrolysable Myr-CoA analogue S-(2-
oxo)pentadecyl-CoA (NHM)54 using 25% PEG 3350, 0.2M KCl, sodium citrate
(pH 5.5). HsNMT2 crystals belong to the orthorhombic space group P212121 with a
single molecule of the complex in the asymmetric unit. For both crystal forms, the
Matthews coefﬁcient is 2.26 Å3/Da corresponding to a solvent content of 45%.
X-ray diffraction data were collected on synchrotron beam lines i02
(l¼ 0.9783Å) and i03 (l¼ 0.9763Å) at the diamond light source, Harwell and
processed using XDS55 and SCALA56 implemented within xia257. Data collection
and reﬁnement statistics are summarized in Table 1. For HsNMT2, data were used
for molecular replacement calculations in the program MOLREP58 using a
coordinate set corresponding to a single chain of HsNMT1 (PDB code 3IU1, 83%
sequence identity) as a search model. For HsNMT1, the coordinates from PDB
code 3IU1 were used directly for reﬁnement using maximum likelihood methods
implemented in REFMAC59. Cycles of reﬁnement using anisotropic temperature
factors were interspersed with model building and adjustment using COOT60.
Complete chains can be traced for both the proteins with the exception of
N-terminal residues preceding Arg115 of NMT1 and Met109 of NMT2
(numbering as in full-length protein). These residues are not deﬁned in the electron
density maps and they are assumed to be disordered. The HsNMT1 protein
structure models display good geometry, with 95% of the residues lying in the
preferred regions of the Ramachandran plot and only a single residue (Phe422)
lying outside of the allowed regions. Electron density maps in the vicinity of the
bound ligand in the structure of HsNMT1-Myr-CoA-1 are better deﬁned for chain
A, as reﬂected by the reﬁned atomic B-factors (Table 1), and it is this active site that
is displayed in the ﬁgures and referred to in the main text. For HsNMT2, the
diffraction data showed a degree of anisotropy along the long axis of the crystal,
contributing to the relatively high R-values during reﬁnement. The lower-
resolution maps are reﬂected in the poorer distribution of the modelled protein
residues in a Ramachandran plot, with 92.9% in the preferred regions, a further
5.2% in the allowed region and seven residues calculated as outliers.
The coordinates and structure factor ﬁles have been deposited in the Protein
Data Bank under the accession codes 4C2X (HsNMT2-NHM), 4C2Y (HsNMT1-
Myr-CoA) and 4C2Z (HsNMT1-Myr-CoA-1).
HeLa cell culture. HeLa cells (Cancer Research UK cell services core facility) were
grown in DMEM (supplemented with 10% FBS and 1% penicillin/streptomycin) in
a humidiﬁed 10% CO2-containing atmosphere at 37 C. Cells were plated 24 h
before treatments. For the spike-in SILAC and SILAC experiments, HeLa cells were
grown in a R10K8 or R0K0 DMEM medium (Dundee Cell Products) supplemented
with 10% dialysed FBS and 1% penicillin/streptomycin for 410 passages. The
incorporation of the R10K8 label was determined to be 497%.
YnMyr labelling and incubation with inhibitor in HeLa cells. Cells were incu-
bated with inhibitor 1 (0, 0.08, 0.2, 0.4, 1 or 5 mM) for 30min. The media of each
plate was then removed and replaced by culture media containing the inhibitor and
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YnMyr (typically 20 mM). In each plate, the total amount of DMSO was normalized
to the maximum amount of DMSO used. Cells were incubated for several hours
(typically 24 h) before cell lysis. To study YnMyr labelling during apoptosis, cells
were incubated for 30min with STS (1mM) and inhibitor 1 (0, 0.08, 0.2, 0.4 or
1 mM), and then YnMyr (20 mM) was added and the cells were incubated for a
further 7 h before cell lysis. After treatment, cells were washed with PBS (2 ) and
lysed on ice using the following lysis buffer: PBS 1 , 0.1% SDS, 1% Triton X-100,
1 EDTA-free complete protease inhibitor (Roche Diagnostics). Lysates were kept
on ice for 20min and centrifuged at 17,000 g for 20min to remove insoluble
material. Supernatants were collected and stored at  80 C. Protein concentration
was determined using the Bio-Rad DC Protein Assay.
Preparation of spike-in standards. To study co-translationally N-myristoylated
proteins (CoTMyr), cells were grown in the heavy media (R10K8) and were treated
for 24 h with 20 mM YnMyr (total amount of DMSO: 0.05%), and then lysed and
treated as above. To prepare the Spike-in SILAC standard for the study of post-
translationally N-myristoylated proteins (PTMyr), cells were grown in the heavy
media (R10K8) as described above and were pre-treated for 30min with STS
(1mM). Cells were then treated with YnMyr (20 mM) and STS (1 mM) for 7 h (total
amount of DMSO: 0.05%).
Preparation of YnMyr ±STS SILAC samples. To study YnMyr labelling during
apoptosis, HeLa cells in R10K8 medium (heavy cells) were pre-incubated for 30min
with STS (1mM), whereas cells in R0K0 medium (light cells) were treated for 30min
with DMSO. To both heavy and light cells was added YnMyr (20mM) for 7 h.
CuAAC and in-gel ﬂuorescence. Lysates were thawed on ice. Proteins (100 mg)
was taken and diluted to 1mgml 1 using the lysis buffer. A click mixture was
prepared by adding reagents in the following order and by vortexing between the
addition of each reagent: the capture reagent (1 ml, stock solution 10mM in DMSO,
ﬁnal concentration 0.1mM), CuSO4 (2 ml, stock solution 50mM in DMSO, ﬁnal
concentration 1mM), tris(2-carboxyethyl)phosphine (TCEP) (2 ml, stock solution
50mM in DMSO, ﬁnal concentration 1mM), tris(benzyltriazolylmethyl)amine
(TBTA) (1 ml, stock solution 10mM in DMSO, ﬁnal concentration 0.1mM). Click
mixture (6ml) was added to each sample. The samples were vortexed at room
temperature (RT) for 1 h. Next, 1ml ice-cold MeOH and EDTA (ﬁnal con-
centration 10mM) were added to each sample. The samples were quickly vortexed
and kept at  80 C overnight. The samples were centrifuged at 17,000 g for 30min
to pellet precipitated proteins. The pellets were washed with 1ml ice-cold MeOH
and dried. Seventy-ﬁve microlitre 2% SDS in PBS, 10mM EDTA was added and
the samples were vortexed. Once the proteins were completely dissolved, 25 ml of
4 SLB (sample-loading buffer prepared by mixing 4 NuPAGE LDS sample
buffer: b-mercaptoethanol 5:1) was added (ﬁnal concentration of proteins
1mgml 1). The samples were boiled for 5min, centrifuged at 1,000 g for 2min
and loaded on a SDS–polyacrylamide gel electrophoresis gel. Typically, 10 mg of
proteins were loaded on the gel. After the run, the gel was washed with MilliQ
(3 ) and soaked in ﬁxing solution (40% MeOH, 10% acetic acid, 50% water) for
20min, washed with MilliQ (3 ). The ﬂuorescence on the gel was detected using
an Ettan DIGE Imager (GE Healthcare) and the protein loading was checked by
Coomassie. The quantiﬁcation of ﬂuorescent bands to calculate in-cell tagging IC50
was carried out using ImageJ. The signal was measured by integrating the area
under each band of interest using the ‘gel analyzer’ function and normalized
relative to no inhibition (YnMyr). The signal was normalized to the total protein
loading by integrating the gel stained with Coomassie. In-cell tagging IC50s (TC50s)
were determined using GraFit 7.0 (Erithacus Software Ltd) by non-linear regres-
sion ﬁtting.
N-myristoylated protein enrichment and in-gel ﬂuorescence. For enrichment of
myristoylated proteins, 100ml of lysate was captured by CuAAC as described above.
After protein precipitation, the pellet was resuspended in 2% SDS in PBS, 10mM
EDTA (20ml). Once the pellet was completely dissolved, 80ml of PBS was added
(ﬁnal concentration 1mgml 1, 0.4% SDS). Twenty microlitre was reserved for the
‘before pull-down’ sample. The remaining 80ml was diluted to 0.2% SDS and
0.5mgml 1 by the addition of 80ml PBS. Dynabeads MyOne Streptavidin C1
(15ml) were washed with 0.2% SDS in PBS (3 250ml). The sample was added to the
beads and the beads were gently vortexed for 90min. The supernatant was removed
and the beads were washed with 0.2% SDS (3 250ml). Thirty microlitre of 2% SDS
in PBS and 10ml 4 SLB were added to the beads and the beads were boiled for
10min. SLB (7ml) was added to the ‘before pull-down’ sample and 7ml SLB was
added to 20ml of supernatant. Both samples were boiled for 5min. Samples were
centrifuged at 1,000 g for 2min and loaded on a SDS–polyacrylamide gel electro-
phoresis gel (‘before pull-down’ sample: 10ml (7.5mg of proteins); supernatant: 10ml
(7.5mg of proteins); pull-down: 15ml (30mg of proteins). Full size original images for
all cropped gels can be found in Supplementary Fig. 12.
Western Blot analysis. Proteins were transferred to polyvinylidene diﬂuoride
membranes using a wet transfer setup. Membranes were washed with TBS-T (1
TBS, 0.1% Tween-20), blocked (5% dried skimmed milk in TBS-T), washed with
TBS-T (3 ), incubated with the appropriate primary antibody (c-SRC (Cell sig-
naling technology, 2123, 1/500 dilution); PMSC1 (Atlas, HPA000872, 1/500 dilu-
tion); PKA (Cell Signaling Technology, 5842S, 1/500 dilution), FLOT2 (Atlas
antibodies, HPA002946, 1/500 dilution), MARC2 (Atlas antibodies, HPA015085,
1/150 dilution), HCCS (Atlas antibodies, HPA002946, 1/500), DYNC1I2 (Abcam,
ab96288, 1/250 dilution), NMT1 (Atlas antibodies, HPA022963, 1/500 dilution),
PARP (Santa Cruz, sc8007, 1/250 dilution), BID (Cell Signaling, 2002S, 1/250),
FLAG (Abcam, ab1162, 1/1000 dilution) and Actin (Abcam, ab3280, 1/1,000
dilution) in blocking solution overnight, washed with TBS-T (4 ), incubated
with the appropriate secondary antibodies in blocking solution for 1 h, washed
with TBS-T (4 ) and developed with Luminata Crescendo Western HRP
substrate (Millipore) according to the supplier’s protocol and on a Fujiﬁlm LAS-
3000 imager. Full size original images for all cropped blots can be found in
Supplementary Fig. 12.
CuAAC and sample preparation for MS-based proteomics. CuAAC reaction
was carried out with 2mgml 1 of proteins (CoTMyr) and 0.6mgml 1 (PTMyr).
The spike-in standard was mixed with the lysates treated with increasing amount of
inhibitor and YnMyr in a 1:2 (CoTMyr) or 1:3 (PTMyr) ratio of lysate to spike-in
standard, before the CuAAC reaction. The same spike-in standard was used for all
the samples belonging to a speciﬁc set (CoTMyr or PTMyr) to allow the com-
parison between samples within this set. Proteins were captured by adding a
mixture of the capture reagent AzTB (ﬁnal concentration 0.1mM), CuSO4 (ﬁnal
concentration 1mM), TCEP (ﬁnal concentration 1mM) and TBTA (ﬁnal con-
centration 0.1mM). The samples were vortex-mixed for 1 h before the addition of
EDTA (ﬁnal concentration 10mM), methanol (4 volumes), chloroform (1 volume)
and water (3 volumes). The samples were vortex-mixed brieﬂy and centrifuged at
10,000 g for 5min, and the resulting pellets were washed twice with methanol (4
volumes) and dried. After protein precipitation, the pellet was resuspended in 2%
SDS in PBS, 10mM EDTA (10mgml 1 of proteins). Once the pellet was com-
pletely dissolved, PBS was added to dilute the sample (ﬁnal concentration
1mgml 1, 0.2% SDS). NeutrAvidin agarose resin (Thermo Scientiﬁc) was washed
with 0.2% SDS in PBS (3 ). Typically 50ml of bead slurry was used for 1mg of
lysate. The sample was added to the beads and the enrichment was carried out for
2 h at RT. The supernatant was removed and the beads were washed with 1% SDS
in PBS (3 ), 4M urea in 50mM ammonium bicarbonate, AMBIC (3 ), 50mM
AMBIC (5 ). For a 50ml bed of beads, samples were reduced (2.5 ml of 100mM
DTT in 50mM AMBIC) at 60 C for 30min and allowed to cool to RT. The beads
were washed with 2 50mM AMBIC. Cysteines were alkylated (2.5 ml of 100mM
iodoacetamide in 50mM AMBIC) at RT for 30min in the dark. The beads were
washed with 2 50mM AMBIC. Trypsin (2 mg Sequencing Grade Modiﬁed
Trypsin (Promega) dissolved in 50mM AMBIC) was added to the beads and the
samples were placed on a shaker and digested overnight at 37 C. The samples were
centrifuged and the supernatant (SN1) was transferred into clean tubes. The beads
were washed with 0.1% aqueous formic acid, and these washes (SN2) were com-
bined with SN1 fractions. The solutions were stage-tipped according to a published
protocol61. Elution from the sorbent (SDB-XC poly(styrenedivinylbenzene)
copolymer, from 3M) with 70% acetonitrile in water was followed by speed-vac-
assisted solvent removal, reconstitution of peptides in 0.5% triﬂuoroacetic acid, 2%
acetonitrile in water and transferred into LC-MS sample vials.
LC-MS/MS analysis. The analysis was performed using an Acclaim PepMap
RSLC column 50 cm 75 mm inner diameter (Thermo Fisher Scientiﬁc) using a
2-h acetonitrile gradient in 0.1% aqueous formic acid at a ﬂow rate of
250 nlmin 1. Easy nLC-1000 was coupled to a Q Exactive mass spectrometer via
an easy-spray source (all Thermo Fisher Scientiﬁc). The Q Exactive was operated in
data-dependent mode with survey scans acquired at a resolution of 75,000 at m/z
200 (transient time 256ms). Up to 10 of the most abundant isotope patterns with
charge þ 2 or higher from the survey scan were selected with an isolation window
of 3.0m/z and fragmented by higher-energy collision dissociation (HCD) with
normalized collision energies of 25. The maximum ion injection times for the
survey scan and the MS/MS scans (acquired with a resolution of 17,500 at m/z 200)
were 20 and 120ms, respectively. The ion target value for MS was set to 106 and for
MS/MS to 105, and the intensity threshold was set to 8.3 102.
Proteomics data analysis. The data were processed with MaxQuant version
1.3.0.5 (ref. 62), and the peptides were identiﬁed from the MS/MS spectra searched
against human Swissprotþ Isoforms database (July 2013) using the Andromeda
search engine. Cysteine carbamidomethylation was used as a ﬁxed modiﬁcation
and methionine oxidation as a variable modiﬁcation. For in silico digests of the
reference proteome, the following peptide bond cleavages were allowed: arginine or
lysine followed by any amino acid (a general setting referred to as trypsin/P);
arginine or lysine followed by any amino acid as well as any amino acid followed by
glycine (this setting was applied speciﬁcally for PTMyr-modiﬁed peptide searches).
Up to two missed cleavages were allowed. The FDR was set to 0.01 for peptides,
proteins and sites. Other parameters were used as pre-set in the software. ‘Unique
and razor peptides’ mode was selected to allow for protein grouping; this calculates
ratios from unique and razor peptides (razor peptides are uniquely assigned to
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protein groups and not to individual proteins). Data were analysed using Microsoft
Ofﬁce Excel 2007, Perseus version 1.3.0.4, Origin 8.5 and GraFit 7.0.
Label-free quantiﬁcation data analysis. LFQ experiments in MaxQuant were
performed using the built-in LFQ algorithm63 enabling the ‘match between runs’
option (time window 2min), and were processed with Perseus version 1.3.0.4. The
experiment comprised four biological replicates treated with Myr and four
biological replicates treated with YnMyr. The LFQ is based on intensities of
proteins calculated by MaxQuant from peak intensities and based on the ion
currents carried by several peptides whose sequences match a speciﬁc protein or a
protein group to provide an approximation of abundance. The replicates were
grouped together. The YnMyr protein group was ﬁltered to obtain at least three
valid values across the four replicates and in addition at least two peptides (unique
and razor) per valid value. Label-free intensities were logarithmized (base 2) and
empty values were imputed with random numbers from a normal distribution,
whose mean and s.d. were chosen to best simulate low abundance values close to
noise level (impute criteria: width 0.1 and down shift 1.8). A modiﬁed t-test with
permutation-based FDR statistics was applied (250 permutations; FDR¼ 0.001;
S0¼ 1). The data were further ﬁltered by keeping only the proteins with an LFQ
enrichment higher than 4. The LFQ enrichment was determined by ﬁrst calculating
the mean value of the LFQ intensities of the Myr replicates and the mean value of
the LFQ intensities of the YnMyr replicates. The mean of YnMyr intensities was
then divided by the mean of Myr intensities.
Spike-in SILAC (CoTMyr) data analysis. Light/heavy ratios, corresponding to
the amount of protein in the lysate with increasing amount of inhibitor in relation
to the spike-in standard, found for each protein, each condition (concentration of
inhibitor) and each replicate (ﬁve biological replicates) were determined by Max-
Quant as explained above. The data were ﬁltered to keep only proteins with a
N-terminal MG motif and three valid values per protein. For each replicate, the
values were normalized to the sample with 0 mM inhibitor 1. To compare the six
conditions (six concentrations of inhibitor), an analysis of variance was performed
with Benjamini Hochberg correction at an FDR of 0.05. In addition, hierarchical
clustering was performed in Perseus, where proteins sensitive to NMT inhibition
were clustered together while the insensitive proteins were in different clusters. The
data were then manually inspected. Proteins that were dose-dependently sensitive
to NMT inhibition, with a minimal ratio o0.3, were deﬁned as ‘N-myristoylated
with high conﬁdence’. In-cell IC50 values were determined using the mean values of
the ratios between the ﬁve replicates and determined using GraFit 7.0 (Erithacus
Software Ltd) by non-linear regression ﬁtting (IC50 back-corrected function).
When proteins had a low number of unique peptide (0 or 1 in the highest con-
centrations of inhibitors), they were classiﬁed as low-conﬁdence hits. Proteins with
an ambiguous dose response (lowest ratios do not dropo0.3 but dropo0.6) were
classiﬁed as ‘N-myristoylated with low conﬁdence’. Other proteins were classiﬁed
as ‘not N-myristoylated with high/low conﬁdence’.
SILAC experiment (YnMyr±STS) data analysis. The heavy samples originated
from cells treated with YnMyrþ STS and the light samples originated from cells
treated with YnMyr. Ratios H/L (heavy/light) were determined for each protein in
three biological replicates (cells harvested from separate plates) with MaxQuant
1.3.0.5 following LC-MS/MS analyses. During the analysis in Perseus, only proteins
quantiﬁed in at least two biological replicates (two valid values out of three) were
kept. The ratios H/L were divided by 3, as the samples were mixed after cell lysis in
a 3:1 ratio heavy to light. The Log2 values of the ratios were determined and a one-
sample test (t-test, FRD¼ 0.05, side: left), where the differences from the median
H/L distributions were analysed, was performed.
Identiﬁcation of the modiﬁed peptide with AzKTB or AzRTB. MaxQuant uti-
lizes a scoring algorithm when matching experimental MS/MS spectra with a
library of theoretical spectra generated from in silico digestion of proteins within
databases selected for the search62,64,65. The algorithm is used to evaluate the
quality of peptide–spectrum matches (PSMs). A number of factors, such as the
number of product ions detected or their intensities, contribute to the score. To
each PSM, MaxQuant also attributes a Dscore, which is a difference between scores
associated with the match to the best peptide candidate and the second best match
within the database; the higher the score and the Dscore, the more reliable the
identiﬁcation. MaxQuant utilizes a predeﬁned FDR value (0.01 for all searches) to
generate score thresholds separately for different populations of peptides, for
example, different peptide length, nature and number of modiﬁcations and so on.
To reduce a possibility for a false-peptide sequence assignment even further, Dscore
thresholds were additionally applied (20 for AzRTB and 40 for AzKTB) in our
analysis. See Supplementary Data 2 and 4 for the per-protein Dscore, and
Supplementary Figs 7 and 10 for examples of sequence analysis by MS/MS
assignments.
Spike-in SILAC (PTMyr) data analysis. Ratios light/heavy (corresponding to
amount of protein in the lysate with increasing amount of inhibitor/spike-in
standard) found for each protein, each condition (concentration of inhibitor) and
each replicate (n¼ 3 biological replicates) were determined by MaxQuant 1.3.0.5
following LC-MS/MS analyses. The data were ﬁltered to obtain at least three valid
values per protein. For each replicate, the values were normalized to the sample
with 0 mM of inhibitor, thus the amount of protein in the 0 mM of inhibitor samples
was set as 1. To compare the ﬁve conditions (ﬁve concentrations of inhibitor), an
analysis of variance was performed with Benjamini Hochberg correction
(FDR¼ 0.05). Co-translationally N-myristoylated proteins were also tagged with
YnMyr, but they were excluded (according to the identiﬁed substrates in
Supplementary Data 2). The data were then manually inspected. Proteins were
deﬁned as substrates when their mean ratio was o0.5 in the sample with the
highest concentration of inhibitor, for which quantiﬁcation was available. Proteins
that were not enriched in the STS-treated sample (mean ratio B1.0, see
Supplementary Data 4), but were sensitive to the presence of inhibitor 1, were
classiﬁed as post-translationally myristoylated-low conﬁdence. The unique peptides
detected for each protein were mapped to the protein sequences (see
Supplementary Fig. 5). The cleavage site was predicted using the CASVM server
(see Bioinformatics).
Whole-lysate ± inhibitor data analysis. The experiment comprised three bio-
logical replicates for each sample (0 day treatment, 1 day treatment) spiked-in with
heavy HeLa cells not treated with the inhibitor. Ratios H/L (corresponding to the
amount of protein in the spike-in standard/in the lysate treated with the inhibitor
for 0–1 day) found for each protein, each condition and each replicate (three
biological replicates) were determined by MaxQuant as explained above. The
replicates were grouped together. The group were ﬁltered to obtain at least two
valid values. Ratios were logarithmized (base 2). Modiﬁed t-tests with permutation-
based FDR statistics were applied (250 permutation, 5%, two tailed, s0¼ 0)
between the two groups. Data output can be found in Supplementary Data 5.
Bioinformatics. Myristoylation predictions were carried out using the two online
predictors (Myr predictor19 and Myristoylator18). The Myr predictor divides
proteins into groups with three levels of conﬁdence: R¼ reliable; T¼ twilight,
N¼ not myristoylated, and the myristoylator uses four levels of conﬁdence:
H¼ high probability, M¼medium probability, L¼ low probability, N¼ not
myristoylated. Four levels of myristoylation conﬁdence were deﬁned by combining
the results of the two predictors: N¼ not myristoylated, P¼ probable, L¼ low,
M¼medium, H¼ high. Proteins with probability R (Myr predictor) and H
(Myristoylator), were reported to be myristoylated with a high probability (H).
Proteins with probability R (Myr predictor) and M (Myristoylator) were reported
to be myristoylated with a medium probability (M).
In the present study, proteins were described as palmitoylated when they were
identiﬁed as palmitoylated in at least one proteomic experiment, as reported by
Wilson et al.12 (þ : found in one study, þ þ : found in two studies; þ þ þ :
found in three studies; þ þ þ þ : found in four studies), or reported as
palmitoylated in the UniProtKB/Swiss-Prot database (indicated as u in the data
set). GPI-anchored proteins are reported as found in the UniProtKB/Swiss-Prot
database.
To predict proteolysis cleavage sites, the CASVM server was used (http://
www.casbase.org/casvm/server/index.html) with the following options: scanning
window size of P14-P100 and P1 residue aspartic or glutamic acid. The cleavage site
was correlated with the PROTOMAP database (http://www.scripps.edu/cravatt/
protomap/) and the CASBAH database66 (http://bioinf.gen.tcd.ie/casbah/).
MTS assay. HeLa cells were seeded in a 96-well plate 24 h before treatment. Cell
suspensions were prepared in the appropriate growth media using the following
concentrations: 100,000 cellsml 1 for 24 h treatment, 50,000 cellsml 1 for 48 h
treatment, 32,000 cellsml 1 for 72 h or 10,000 cellsml 1 for 1 week treatment.
Fifty microlitre of cell suspension was transferred to wells B–G in columns 2–11 of
a 96-well plate. Growth media (100 ml) was added to the outer wells. Twenty-four
hours after seeding, 50 ml of growth media containing DMSO (positive control;
maximum amount of DMSO used for the inhibitor dilutions, 0.04%) or puromycin
(negative control; 4 mgml 1, 50 ml, ﬁnal concentration in the plate 2 mgml 1) or
different concentrations of inhibitor were prepared (same ﬁnal percentage of
DMSO; dilution factor¼ 2; typically triple dilutions starting from 20 mM; ﬁnal
concentration in the plate starting from 10 mM) were added to the cells. Twenty-
four, 48, 72 or 164 h later, MTS reagent (Promega) was added according to the
supplier’s protocol. Absorbance was measured at 490 nm after 2 h. The average of
absorbance values of the negative control was subtracted from every value. The
metabolic activity was calculated as a percentage relative to the positive control.
EC50 values were calculated by ﬁtting the data to the IC50 function using GraFit 7.0
(Erithacus Software Ltd).
Overexpression and analysis of Cul4B[1-590]-FLAG. HeLa cells (4 105) were
reverse transfected with plasmid encoding for Cul4B (aa 1–590) utilizing TurboFect
transfection reagent (17 h) according to the manufacturer’s instructions. Next, the
media was changed followed by treatment with STS (1 mM), NMT inhibitor 1
(1 mM) or vehicle (DMSO). After 1 h incubation, the cells were treated with YnC12
(20 mM, 6 h) and then lysed (PBS, 1% Triton, protein inhibitor). Total proteins
(50 mg) was applied onto the washed Anti-FLAG afﬁnity resin (40 ml of 50% slurry)
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and incubated on a rotation wheel at 4 C for 2 h. Following the IP step, the
supernatant was removed and beads washed (3 , lysis buffer). Next, click reaction
with N3-TAMRA was performed on beads utilizing the standard conditions (as
above) and excess ﬂuorophore was removed by washing (as above). The beads were
then boiled in 2% SDS/PBS (25 ml) at 95 C for 10min. The supernatant was
removed and 15ml was loaded on a gel. Pull-downed proteins were visualized by
in-gel ﬂuorescence followed by WB (a-FLAG). The supernatant from the IP step
was utilized as loading control for WB. Proteins were precipitated (MeOH/CHCl3)
and resuspended in 2% SDS/PBS (50 ml, 1mgml 1). Total proteins (10mg) were
loaded on a gel and analysed by a-actin WB.
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